Hippocampal neurons in pre-clinical Alzheimer’s disease

Permalink
https://escholarship.org/uc/item/6rb1993n

Journal
Neurobiology of Aging, 25(9)

ISSN
0197-4580

Authors
West, Mark J
Kawas, Claudia H
Stewart, Walter F
et al.

Publication Date
2004-10-01

DOI
10.1016/j.neurobiolaging.2003.12.005

Copyright Information
This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed
Hippocampal neurons in pre-clinical Alzheimer’s disease

Mark J. West¹,¹, Claudia H. Kawas², Walter F. Stewart³,³, Gay L. Rudow⁴, Juan C. Troncoso*¹

¹ Department of Neurobiology, Institute of Anatomy, Building 234, University Park, Aarhus 8000, Denmark
² Irvine Institute for Brain Aging and Dementia, University of California, 1121 Gillespie N.R.F., Irvine, CA 92697-4540, USA
³ Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, MD 21205-2179, USA
⁴ Departments of Pathology (Neuropathology) and Neurology, Johns Hopkins University School of Medicine, Ross Building 558, 720 Rutland Ave., Baltimore, MD 21205, USA

Received 28 April 2003; received in revised form 8 December 2003; accepted 9 December 2003

Abstract

In a previous study of hippocampal neurons in aging and AD [Lancet 344 (1994) 769], we demonstrated that the loss of neurons in the CA1 region was disease-specific and not related to aging. In the present study, we examined for loss of hippocampal neurons in preclinical AD, a period during which there are abundant amyloid deposits in the brain but no evidence of cognitive decline. We examined the postmortem brains of 33 subjects from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Alzheimer’s Disease Research Center. Using unbiased stereology, we estimated the total number of neurons in the granule cell layer, hilus, CA3-2, CA1, and subiculum of AD (n = 14), preclinical AD (n = 8), and age-matched control subjects (n = 11). The results from the present study confirm our previous finding of significant neuronal losses in the CA1 (48%), hilus (14%), and subiculum (24%) in AD [Lancet 344 (1994) 769]. However, we did not observe a significant loss of neurons in CA1 or any of the other subdivisions of the hippocampus in preclinical AD.

© 2004 Elsevier Inc. All rights reserved.

Keywords: Hippocampal neurons, Subiculum, Alzheimer’s disease (AD)

1. Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized clinically by dementia and ne-robehavioral deterioration [9,24]. In demented subjects with AD, the pathological hallmarks are Aβ amyloid deposits, senile plaques (SP), neurofibrillary tangles (NFT), degeneration of synapses [34], and loss of neurons [10,26,39]. However, not all of these pathological changes have been characterized before the onset of cognitive decline, i.e., in the preclinical stages of AD. The development of NFT and SP has been described in preclinical AD [25], but there is only a single stereological study of the number of neurons in the hippocampus in preclinical AD [26]. The validity of the concept of a preclinical stage in AD is supported by longitudinal clinical studies of mild memory changes followed by an accelerated decline [6,15,19,33] and by clinical-pathological studies that report the presence of the characteristic lesions of AD in cognitively normal individuals [1,23,35,36]. Some of these studies suggest that the Aβ deposits in the brain may precede the onset of cognitive decline by a decade or more [27,36], indicating the presence of a wide temporal window for neuronal protective therapeutic intervention. An important caveat with the concept of preclinical AD is that we are making the assumption that those individuals, had they live long enough, would have developed clinical AD. This is not certain and we cannot rule out the possibility that some individuals can tolerate substantial AD neuropathological lesions, but never become demented.

In a previous study we described the pattern of loss of hippocampal neurons in normal aging and AD [39] and concluded that the most distinctive lesion of AD was the loss of neurons in the CA1 region. Moreover, we found that the degeneration in CA1 was disease-specific and not related to aging, per se. These findings have prompted us to examine whether or not a significant loss of hippocampal neurons, in particular in CA1, occurs in preclinical AD, that is, during a
period in which there are abundant amyloid deposits present in the brain but no evidence of cognitive decline. Thus, in the present study, we extend our stereological evaluation of the number of hippocampal neurons to the preclinical stage of AD.

2. Materials and methods

We used unbiased stereological techniques to examine the postmortem brains of subjects followed by the Baltimore Longitudinal Study of Aging (BLSA) and the Johns Hopkins University Alzheimer’s Disease Research Center (ADRC). Estimates of the total number of neurons in each of five subdivisions of the hippocampus were made in the left hippocampus of 33 subjects.

2.1. Subjects

The subjects were placed into one of three diagnostic categories: AD, preclinical AD, and age-matched controls. The AD (n = 14) subjects had clinical histories of dementia and their brains contained a sufficient number of neuritic Aβ plaques (CERAD plaques scores B or C) to meet the CERAD criteria for definite AD [21]. The preclinical AD subjects (n = 8) were cognitively intact and their MMSE scores were ≥26, but their brains contained substantial numbers of neuritic Aβ plaques (CERAD plaque scores B or C) [21]. The age-matched controls (n = 11) were cognitively intact and their MMSE were ≥26, and their brains had no or minimal pathologic changes that ranged from no Aβ deposits, to a few diffuse Aβ plaques, to sparse neuritic Aβ plaques (CERAD neuritic plaque score 0 or A). Many controls exhibited NFTs in hippocampus and entorhinal cortex.

The subjects for this study were recruited from the BLSA (n = 25) and JHU-ADRC (n = 8). The BLSA is a longitudinal study of normal aging conducted by the National Institute on Aging (NIA). At enrollment and at subsequent 1 year intervals, all BLSA subjects were examined according to BLSA protocols [29], complemented by a comprehensive medical history, a standardized neuropsychological examination, and a battery of neuropsychological tests [17,35]. This battery included the Blessed BIMC [3], the Mini-Mental State Examination (MMSE) [8], Free and Cued Selective Reminding Test-Delayed recall [11], Category Fluency (animals) [22], Letter Fluency (“S”) [2], and Trails A and B [5]. In the year between clinical evaluations, participants were administered the telephone version of the BIMC (T-BIMC) [16]. Subjects who showed a decline of two or more points in the T-BIMC were invited to an in-person evaluation. In addition, we completed a postmortem Dementia Questionnaire (DQ) [7,16,30,31] for each participant, interviewing a reliable informant within 1 year of death. ADRC subjects received neurological and neuropsychological evaluations when they entered the program and at subsequent 1 year intervals. The neurocognitive evaluation was similar to that of the BLSA subjects. Table 1 shows the demographic information for all subjects. Neuropsychological test scores (means and ranges) are summarized in Table 2. Subjects with preclinical AD had scores that were similar or even superior to the scores of the control subjects.

2.2. Clinical diagnoses

The diagnostic status of each participant was routinely evaluated during a multidisciplinary diagnostic conference that took into consideration the outcome of evaluations described above and medical records from external sources. Criteria from the Diagnostic and Statistical Manual of Mental Disorders III-R (DSM III-R) were used to make the diagnosis of dementia and NINCDS-ADRDA criteria [20] were used to make the diagnosis of AD. Dementia was diagnosed on the basis of the patient’s history and examination. The clinical diagnosis was made without knowledge of the pathologic diagnosis.

2.3. Neuropathology

The autopsies of all of the subjects were performed by the JHU-ADRC and for most of them the interval between the last clinical evaluation and death was less than 18 months. At autopsy, the left half of the brain was immersion-fixed in 10% buffered formaldehyde for 2 weeks prior to being sectioned coronally into 1 cm thick slabs. For diagnostic purposes, tissue blocks were dissected from frontal, temporal, parietal, occipital, and cingulate cortices, basal ganglia, amygdala, entorhinal cortex; hippocampus; thalamus; brain stem; and cerebellum. The tissue blocks were embedded in paraffin, cut at 10 µm, and stained with hematoxylin–eosin and the Hirano silver method [40]. Selected sections were immunostained with antibodies for Aβ (directed against residues 1–28, a gift from Elan Corporation) and tau (Tau-2 from Sigma) using a standard protocol [18]. The neuropathological diagnosis of AD followed CERAD [21] guidelines. Silver stains were used to determine Braak neurofibrillary scores [4].

2.4. Stereology

For estimating the total number of neurons in the various hippocampal subdivisions, 5–6 large blocks of tissue (1 cm thick) that contained the entire hippocampus region, from the per to the tenia tecta, were dissected from the 1 cm thick coronal slabs on the left side. These blocks were then embedded in paraffin and exhaustively sectioned at a microtome thickness setting of 50 µm. For each individual, a systematic random sample of sections, cut in the coronal plane and selected at 30 section intervals, was collected from the entire series of sections selected from all of the blocks. This resulted in 8–14 sections that spanned the
Table 1
Demographic and neuropathological information on cases and controls

| ID # | Age | Sex | MMSE | CERAD plaque score | Braak NFT stage | Pathological diagnoses |
|------|-----|-----|------|-------------------|-----------------|-----------------------|
|      |     |     |      |                   |                 | Controls/parietal infarct |
| 01   | 84  | M   | 30   | 0                 | II              | Control/lacune          |
| 02   | 72  | M   | 29   | 0                 | II              | Control/remote          |
| 04   | 81  | M   | 30   | 0                 | II              | Control                 |
| 05   | 90  | M   | 30   | 0                 | II              | Control                 |
| 06   | 69  | M   | 29   | 0                 | II              | Control                 |
| 07   | 90  | M   | 29   | 0                 | II              | Control                 |
| 08   | 80  | M   | 29   | A                 | III             | Control                 |
| 09   | 96  | M   | 29   | A                 | IV              | Control                 |
| 10   | 83  | M   | 28   | 0                 | I               | Control                 |
| 11   | 77  | M   | 26   | A                 | II              | Control                 |

Preclinical AD

| ID # | Age | Sex | MMSE | CERAD plaque score | Braak NFT stage | Pathological diagnoses |
|------|-----|-----|------|-------------------|-----------------|-----------------------|
| 12   | 75  | M   | 29   | C                 | III             | AD possible/lacune     |
| 13   | 91  | M   | 30   | C                 | IV              | AD possible            |
| 14   | 72  | M   | 30   | C                 | II              | AD possible            |
| 15   | 93  | M   | 30   | C                 | IV              | AD possible            |
| 16   | 82  | F   | 29   | C                 | II              | AD possible            |
| 17   | 87  | M   | 28   | C                 | III             | AD possible            |
| 18   | 79  | M   | 28   | B                 | II              | AD possible            |
| 19   | 94  | M   | 26   | B                 | IV              | AD possible            |

AD cases

| ID # | Age | Sex | MMSE | CERAD plaque score | Braak NFT stage | Pathological diagnoses |
|------|-----|-----|------|-------------------|-----------------|-----------------------|
| 20   | 74  | M   | 23   | B                 | IV              | AD                    |
| 21   | 83  | M   | 24   | C                 | III             | AD                    |
| 22   | 81  | M   | 19   | C                 | V               | AD                    |
| 23   | 73  | F   | 18   | C                 | V               | AD                    |
| 24   | 92  | F   | 16   | C                 | IV              | AD                    |
| 25   | 59  | M   | 6    | C                 | VI              | AD                    |
| 26   | 86  | M   | 5    | C                 | IV              | AD                    |
| 27   | 85  | F   | 4    | C                 | VI              | AD                    |
| 28   | 96  | M   | 4    | B                 | V               | AD                    |
| 29   | 83  | F   | 3    | C                 | VI              | AD                    |
| 30   | 80  | F   | 3    | C                 | VI              | AD                    |
| 31   | 89  | F   | 0    | C                 | VI              | AD                    |
| 32   | 92  | M   | 0    | B                 | V               | AD                    |
| 33   | 87  | F   | 0    | C                 | VI              | AD                    |

Pathological diagnoses according to CERAD [21].

Table 2
Means and ranges of neuropsychological test scores in controls, preclinical AD subjects and AD cases

|                      | MMSE | Delayed recall | Category fluency | Letter fluency (S’) | Trail A seconds to completion | Trail B seconds to completion |
|----------------------|------|----------------|------------------|---------------------|-------------------------------|------------------------------|
| Controls             | 29 (26-30) | 11.4 (6-15) | 14.4 (9-22) | 14 (9-23) | 42.3 (28-61) | 96.4 (54-152) |
| Preclinical AD       | 28.7 (26-30) | 12.8 (11-15) | 18.1 (14-23) | 18 (12-22) | 45 (33-73) | 126.6 (86-193) |
| AD cases             | 8.9 (0-24) | 2.8 (0-10) | 4.1 (0-10) | 5.5 (0-12) | 247 (126-300) | 280 (180-300) |

In each box, the mean is the top number and the range is in parentheses.

2.5. Estimating the total number of neurons in a hippocampal subdivision

The optical fractionator method [38] was used to estimate the total number of neurons in each hippocampal subdivision of each individual used in the study. This stereological...
method combines fractionator sampling [12] with optical disector counting [13,37]. The number of neurons counted with optical dissectors, \( \sum Q - \) , in a known fraction of the section thickness, tsf; under a known of fraction of the area of the sectional profiles of a subdivision, asf; on a known fraction of the sections that pass through the region of interest, ssf, were used to make an unbiased estimate of the total number of neurons, \( N \), in an individual subdivision. (See Table A.1 and Appendix A for more details.)

2.6. Data and statistical analyses

Summary statistics (mean and median) were derived from the individual estimates of total neuron number made in each of the five hippocampal subdivisions of controls, preclinical AD cases, and AD cases. Statistical differences in the region specific estimates of total neuron number, among the three groups studied, were evaluated using the Wilcoxon Signed Test. This is a rank order non-parametric test suitable for small sample sizes or when values are not normally distributed. For each comparison between groups of size \( n_1 \) and \( n_2 \), each value is assigned a rank order between 1 and \( n_1 + n_2 \). Significance testing is based on a comparison of the sum of the rank scores derived for each group and expressed as a Z-score and associated \( P \)-value. The three groups were compared to each other using the fractional cell count rank for each of the five subdivisions of the hippocampus.

3. Results

Table 1 summarizes the neuropathological observations. Fig. 1 and Table 3 summarize the cell count data for each hippocampal subdivision of each of the three groups. The box plots in Fig. 1 indicate the mean (i.e., horizontal line within the box) and the interquartile range (i.e., the upper and lower limits of the box).

Compared to age-matched controls, the brains of AD cases had significantly fewer neurons in CA1 (48%; \( P < 0.001 \)), subiculum (24%; \( P < 0.05 \)), and hilus (14%; \( P < 0.05 \)). However, no differences in neuron number were present between these two groups in either the granule or the CA2-3 subdivision.

The significant loss of neurons in CA1, detected between controls and AD, persisted (37%; \( P < 0.05 \)) when the analysis was limited to the brains of males (Table 4). However, the difference in the number of neurons in either hilus or subiculum, in males, was not statistically significant.

Compared to the age-matched control group, no differences were observed in any subdivision of the preclinical AD group. In contrast, the comparison between the preclinical AD group and the AD group revealed significantly lower numbers of neurons in the CA1 (44%; \( P < 0.05 \)), but not in other subdivisions of the AD group (Table 3). No significant differences were observed between preclinical AD and control groups or between preclinical AD and AD groups when the analysis was restricted to males (Table 4).

4. Discussion

The results from the present study confirm our previous finding of substantial neuronal loss in the CA1, hilus, and subiculum in AD [39]. This confirmation is notable in that two totally different cohorts and two different unbiased stereological methods were used in these studies. Furthermore,
the present study indicates that preclinical Alzheimer’s disease is not characterized by a significant neuronal loss in CA1 or any of the other subdivisions of the hippocampus.

The first major finding of our study is the confirmation of loss of neurons in CA1, subiculum, and hilus in the AD group. With regard to gender composition and severity of disease, the AD group examined in the present study differs from the sample used in our previous study. Whereas in our original study, all the AD cases were males and in the later stages of the disease, in the present study half of the cases were females and 5 out of 14 cases were of mild to moderate severity, i.e., with MMSE > 16. To examine a possible gender effect on the results, we conducted an additional analysis that excluded females from all diagnostic categories. This analysis demonstrated a significant difference between males in the AD and control groups for CA1 neurons (P = 0.02), but not for subiculum or hilus. It should be noted that three of the seven males in the AD group had MMSE scores
that were \( \geq 19 \). The inclusion of this relatively large number of cases of mild severity may have resulted in a smaller difference between the two groups than was observed in our first study [39]. The relatively mild clinical severity of the disease in the male AD cases, together with the large variability in the preclinical group and the reduction in the size of the groups when making comparisons among the males, may also be responsible for our inability to demonstrate significant differences in the number of hippocampal neurons between preclinical AD and AD groups (Table 4).

Our observations are also consistent with a recent report which described substantial losses of neurons in CA1 both in mild and severe AD (46 and 65%, respectively) [26]. However, another study [32] failed to show AD-related changes in CA1. This result may be explained by contamination of the age-matched control group with mild AD cases. This is a distinct possibility since the clinical data in that report was retrospective and it is not clear if the clinical evaluations were designed to detect changes in mental status or cognitive decline.

The present study of the number of neurons in the hippocampus of preclinical AD cases demonstrates that the total number of neurons in CA1, or any other hippocampal subdivision, is not significantly different from those of controls. However, we found a significant loss \( (P < 0.05) \) in CA1 cell count in cases of AD compared to preclinical cases. These results are in close agreement with those in a previous study [26], which was based on the examination of a segment of the hippocampus and also provided information on the entorhinal cortex. Our results suggest that a majority of the decline in the CA1 cell count is likely to occur between the preclinical phase of the disease and the overt clinical phase. We had only limited power (i.e., 12.6%) to detect a difference between controls and preclinical AD cases. As such, we cannot state whether the process of cell death begins around the preclinical phase. Follow-up studies are required to address this question. Calculations indicate that a sample of 164 preclinical and 164 controls would be required to have 80% power to detect the difference we observed in this study. Although our study had limited power to detect a difference in the number of hippocampal neurons between controls and preclinical AD cases, it should be underscored that the agreement of our observations with those of a previous study [26], also with limited statistical power, strengthens the findings in both.

The absence of differences in hippocampal neuronal counts in the preclinical stage of the disease, compared to controls, implies that the deposition of A\( \beta \) and the development of neuritic plaques in the neocortex precedes significant neuronal death in the hippocampus. In view of the early appearance of NFT in the hippocampus [4], the preservation of hippocampal neurons in preclinical AD is an unexpected observation. An important caveat to our observations, however, is that the preservation of hippocampal neurons does not necessarily mean that these neurons are not affected by the disease. It is possible that pathological changes at the cellular level are well underway and affect the neuronal processes and synapses of these neurons without overt perikaryal changes. In view of the recent study [26] describing the sparing of neurons in entorhinal cortex in preclinical AD, this phenomenon does not appear to be unique to the hippocampus. To determine the temporal relationship of neuronal loss in entorhinal cortex and hippocampus in AD, it would be valuable to examine these two regions in the same brains.

In the present study, the optical fractionator stereological method was used. Accordingly, neurons are directly counted in a known fraction of the region of interest using optical dissector probes. This number times the reciprocal of the fraction of the region sampled is an estimate of the total number of neurons in the region (see Appendix A). In our earlier study [39], we used a two step method to estimate total neuron number, \( N \). This involved determining the numerical density of neurons \( N/V \) with optical dissector probes and then multiplying this density by the volume of the region of interest obtained by point counting, \( V_{REF} \).

Accordingly, \( N = N_{V_{REF}} \). The optical fractionator was chosen for the present study in order to reduce potential biases related to defining the anatomical borders of regions of interest. It is also less sensitive than the \( N/V_{REF} \) method to tissue deformation caused by changes in the thickness of the sections during staining and mounting. The estimates of total neuron number reported in the present study are slightly lower than those of the earlier study. This most likely reflects the lack of inclusion of partial sections at the leading and trailing edges of the \( 1 \) cm thick blocks that contained hippocampal tissue. In theory all sections, whether complete or not, should enter into the sampling scheme.

The existence of significant amyloid deposits and neuritic plaques in the neocortex, prior to the loss of hippocampal neurons, suggests that there is a hierarchical order of involvement of various brain regions during the development of AD. According to this scenario, which is based on the idea that amyloid deposition is a primary event in the development of the disease [28], the disease first affects the neocortex (as evidenced by the presence of abundant amyloid) and then spreads to the hippocampus. The lack of change in hippocampal neuron number, at this stage, may then contribute to the preservation of normal cognitive function in preclinical AD.

Another possible explanation of the severe amyloid and neuritic pathologic changes in the neocortex without significant loss of neurons in hippocampus is that the two are not causally related. It may well be that the loss of hippocampal neurons is not related to the amyloid pathology but to tau abnormalities or other types of insults that may lead or contribute to neuronal death, such as aging, hypoxia, or stress. Studies aimed at evaluating the relationship between these other factors and hippocampal neuronal death may provide a more complete understanding of the mechanisms involved in the loss of neurons in this region, which appears to have...
a direct relationship with the initial phases of cognitive de-
cline in AD patients.

In conclusion, the results from the present study indi-
cate that the number of neurons of the various hippocam-
pal subdivisions remains stable in preclinical AD, during
which there are significant amounts of amyloid deposition
in the neocortex but no cognitive changes. This suggests
that in spite of severe amyloid pathology there may still be
a large temporal window during which cognitive changes,
possibly resulting from hippocampal neuronal loss, can be
prevented.

Acknowledgments

We thank the participants, scientists, and staff of the Bal-
timore Longitudinal Study of Aging. We are also indebted
to Ms. Marylin Peper, Ms. Jackie Wilkins, Ms. Kirsten
Lunding, and Dr. Olga Pletnikova for their excellent tech-

cal assistance, and to Ms. Audrey Horter for preparing
the manuscript. This work was supported by NIA grant AG
05146.

Appendix A

An example of sampling scheme used to make the es-
timates in each of the subdivisions of the hippocampus
is shown in Table A.1. The CE (coefficient of error,

taken at 30 section intervals, after a random start within the first 30 sections), asf:

\[
\text{asf} = \frac{\text{area sampling fraction (asf)}}{H^{2}}
\]

Total fraction

\[
\sum \left( \frac{1}{H_{i}} \right) = \frac{1}{H_{1}} + \frac{1}{H_{2}} + \cdots + \frac{1}{H_{n}}
\]

In Table A.1

| Section sampling fraction (ssf) | GRAN | HBL | CA1-3 | CA1 | SUB |
|-------------------------------|------|-----|-------|-----|-----|
| Area sampling fraction (asf)  | 1/70 | 1/70 | 1/70  | 1/70| 1/70|
| Thickness sampling fraction (tsf) | 1/545 | 1/545 | 1/545 | 1/545| 1/545 |
| (frame), optical dissector area (μm²) | 414 | 414 | 414 | 414 | 414 |
| x and y step (μm) | 414 | 414 | 414 | 414 | 414 |
| (frame)/ (step) | 226 | 226 | 226 | 226 | 226 |
| 1/30 | 1/30 | 1/30 | 1/30 | 1/30 |
| 1/2.3 | 1/2.3 | 1/2.3 | 1/2.3 | 1/2.3 |
| 1/66 | 1/66 | 1/66 | 1/66 | 1/66 |
| 1/79 | 1/79 | 1/79 | 1/79 | 1/79 |
| 1/534 | 1/534 | 1/534 | 1/534 | 1/534 |
| 1/133 | 1/133 | 1/133 | 1/133 | 1/133 |
| 10208 | 10208 | 10208 | 10208 | 10208 |
| 542 | 542 | 542 | 542 | 542 |
| 20 | 20 | 20 | 20 | 20 |
| 46 | 46 | 46 | 46 | 46 |

References

[1] Araiaga PJ, Mastroff K, Hyman BT. Distribution of Alzheimer's type pathological changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992;42:1681–8.
[2] Benton AL, Hamsher KS. Multilingual aphasia examination. Iowa City: AIA Associates; 1980.
[3] Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797–811.
[4] Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59.
[5] Davies AD. The influence of age on trail making test performance. J Clin Psychol 1986;24:96–8.
[6] Elias MF, Beiser A, Wolf PA, Au R, White RB, D'Agostino RB. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol 2000;57:808–13.
[7] Ellis RJ, Jun K, Kawas C, Koller WC, Lyons KE, Jeste DV, et al. Diagnostic validity of the dementia questionnaire for Alzheimer's disease. Arch Neurol 1998;55:360–5.
[8] Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients. J Psychiatr Res 1975;12:189–98.
[9] Folstein MF, Byrne PW. Noncognitive symptoms of Alzheimer disease. In: Terry RD, Kates W, editors. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol 2000;57:808–13.
[10] Folstein MF, Byrne PW. Noncognitive symptoms of Alzheimer disease. In: Terry RD, Kates W, editors. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol 2000;57:808–13.
[11] Grober E, Busche H. Genuine memory deficits in dementia. Dev Neuropsychol 1987;3:13–36.
[12] Gundersen HJ. Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc 1986;143:3–45.
[13] Gundersen HJ, Jørgensen PB, Bendtsen TF, Evans SM, Korbo L, Marcussen N, et al. The new stereological tools: dissector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMS 1988;96:857–81.
[14] Gundersen HJ, Jensen EB, Kien K, Nielsen J. The efficiency of systematic sampling in stereology—reconsidered. J Microsc 1990;159:199–211.
[15] Jacobs DM, Sano M, Dooneief G, Marder K, Bell KL, Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer’s disease: Neurology 1995;45:957–62.
[16] Kavas C, Karagözis H, Resau J, Corna M, Broekmeier R. Reliability of the Blinded Telephonic Information/Memory-Concentration Test. J Geriatr Psychiatry Neurol 1995;8:238–42.
[17] Kavas C, Gray S, Broekmeier R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 2000;54:2072–7.
[18] Martin LJ, Sisodia SS, Kor EH, Cork LC, Delis-Rolle TL, Weidemann A, et al. Amyloid precursor protein in aged noshuman primates. Proc Natl Acad Sci USA 1991;88:1461–5.
[19] Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994;44:1427–32.

[20] McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–44.

[21] Mira SS, Heyman A, McKee D, Sarno SM, Crain BJ, Browzić LM, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–86.

[22] Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–86.

[23] Morris JC, Storandt M, McKeel Jr DW, Rubin EH, Price JL, Grant EA, et al. Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology 1996;46:707–19.

[24] Morris JC. Clinical presentation and course of Alzheimer disease. In: Terry RD, Katzman R, Bick KL, Sisodia SS, editors. Alzheimer disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 11–24.

[25] Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 1999;45:583–602.

[26] Sandberg G, Stewart W, Smialek J, Troncoso JC. The prevalence of the neuropathological lesions of Alzheimer’s disease is independent of race and gender. Neurobiol Aging 2001;22:169–75.

[27] Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 1999;399:823–30.

[28] Sherrington DS, McKeel D, Anderson S, Smith N, Smith A, et al. Neuronal loss in the entorhinal cortex and temporal lobe in preclinical Alzheimer’s disease. Acta Neurol Scand 2001;103:187–92.

[29] Siemers ER, Plassman BL, Federman DD, Yaffe K. Incidence and predictors of mild cognitive impairment and Alzheimer’s disease: results from the Epidemiology of Cognitive Impairment in Aging (ECIA) Study. J Gerontol A Biol Sci Med Sci 2004;59A:219–27.

[30] Silverman JM, Brotman JM, Mohs RC, Davis KL. Reliability of the family history method in genetic studies of Alzheimer’s disease and related dementias. Am J Psychiatry 1998;155:1279–82.

[31] Silverman JM, Keefe RS, Mohs RC, Davis KL. A study of the reliability of the family history method in genetic studies of Alzheimer disease. Alzheimer Dis Assoc Disord 1989;3:218–23.

[32] Simic G, Kostovic I, Wadland B, Bogdanovic N. Volume and number of neurons of the human hippocampus formation in normal aging and Alzheimer’s disease. J Comp Neurol 1997;379:482–94.

[33] Small BJ, Pratiglione L, Vitanen M, Wadland B, Buckman L. The course of cognitive impairment in preclinical Alzheimer disease: 3- and 6-year follow-up of a population-based sample. Arch Neurol 2000;57:839–44.

[34] Terry RD, Masliah E, Hansen L. The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations. In: Terry RD, Katzman R, Bick KL, Sisodia SS, editors. Alzheimer disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 187–206.

[35] Troncoso JC, Martin LJ, Dal Fonta G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 1996;17:365–71.

[36] Troncoso JC, Cataldo AM, Nixon RA, Barnett RL, Lee MK, Chedekel F, et al. Neuropathology of preclinical and clinical late-onset Alzheimer’s disease. Ann Neurol 1998;43:673–6.

[37] West MJ, Gundersen H. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 1990;296:1–22.

[38] West MJ, Small BJ, Pratiglione L, Vitanen M, Wadland B, Buckman L. The course of cognitive impairment in preclinical Alzheimer disease: 3- and 6-year follow-up of a population-based sample. Arch Neurol 2000;57:839–44.

[39] Yamamoto T, Hirano A. A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer’s neurofibrillary tangles. Neuropathol Appl Neurobiol 1986;12:3–9.